Bicarbonate

Bicarbonate

SCHEMBL3397279

N.N.O=C(O)O.O=C([O-])[O-].[K+].[K+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.50
CA1 P00915 4/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
FAHD1 Q6P587 1/20 0.50
MEN1 O00255 1/20 0.40
LDHA P00338 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.31
ACHE P22303 1/20 0.31
FFAR3 O14843 1/20 0.31
LCK P06239 1/20 0.31
FYN P06241 1/20 0.31
CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL9133995 0.95 CA4 (0.58) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL14763676 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL9010920 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL9512094 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL18042414 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL7762411 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL1919132 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL17309684 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL163255 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1
Bicarbonate SCHEMBL17911933 0.95 CA1 (0.56) CA4CA1CA2CA9FAHD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247596-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS Natco Pharma Limited (IN) 2010-11-10 EP claimed
WO-2009098715-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS NATCO PHARMA LIMITED (IN) 2009-08-13 WO claimed
CN-119301305-A Circuit board copper chloride etching waste liquid precipitation treatment recycling method and device 叶涛 2025-01-10 CN disclosed
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 US disclosed
EP-2247596-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS Natco Pharma Limited (IN) 2010-11-10 EP disclosed
WO-2009098715-A2 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS NATCO PHARMA LIMITED (IN) 2009-08-13 WO disclosed
US-20040033435-A1 Underlayer of a water-insoluble and alkali-soluble resin; image-recording layer of the resin plus an infrared absorbent; for making a multilayer infrared laser positive-working printing plate FUJI PHOTO FILM CO., LTD. 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS DPYD, TYMP, TYMS CA4 3005/4885CA1 3985/4885CA2 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.